InvestorsHub Logo
Followers 3
Posts 83
Boards Moderated 0
Alias Born 07/17/2014

Re: None

Tuesday, 01/06/2015 12:32:16 PM

Tuesday, January 06, 2015 12:32:16 PM

Post# of 1493
As everybody here knows there are several competitive anti-obesity drugs either to be marketed soon or awaiting approval by the FDA sooner or later.

On December 23rd Novo Nordisk's Saxenda was was approved by the FDA.

This might get approval very soon:
VBLOC device called Maestro by Enteromedics
Maestro
chances

Zafgen phase 2 and 3
Beloranib

Janssen
Canagliflozin
seeking alpha 2014-11-17

Rhythm 2x phase 2
Relamorelin

If obesity market continues to develop, in spite of an increasing number of drugs Orexigen has great potential to become a big player in that market. Analysts estimate the obesity market to sixfold till 2020!
And don't forget the potential Orexigen has in the EU as there it is almost the only company with an approved anti-obesity drug.

Hopefully the Q4/14 figures are positive and pps rises...

GLTA
TwoPack











Join InvestorsHub

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.